Similar to other PLGGs, CD133+/CD15+ and CD133+/CD15− were barely detectable (<1%), while CD133−/CD15+ cells were the major subpopulation, accounting for 64.1% in patient tumor (Figure 2B). Here, PROM1 is linked to neoplasm.